← companies

Amgen (AMGN)

point-in-time fundamentals

The latest fundamentals for Amgen that were publicly knowable as of 2026-02-13, straight from its SEC filings. Every value is stamped with the date it first became public — so a backtest of AMGN can only see what was real at the time. No lookahead bias.

Latest knowable fundamentals

ConceptFYFirst-reported valueBecame public
RevenueFY2025$36.8B2026-02-13
Net incomeFY2025$7.7B2026-02-13
Operating cash flowFY2025$10.0B2026-02-13
Total assetsFY2025$90.6B2026-02-13
Stockholders' equityFY2025$8.7B2026-02-13
Diluted EPSFY2025$14.232026-02-13
Diluted sharesFY20250.54B sh2026-02-13

Revenue, as first reported

What AMGN's annual revenue was on the day each 10-K was filed — the honest number a backtest could have used.

Fiscal yearRevenue (first reported)Filed
FY2025$36.8B2026-02-13
FY2024$33.4B2025-02-14
FY2023$28.2B2024-02-14
FY2022$26.3B2023-02-09
FY2021$26.0B2022-02-16
FY2020$25.4B2021-02-09
get this via API
curl "https://tradevodata.com/v1/fundamentals?ticker=AMGN&as_of=2023-06-30" \
  -H "x-api-key: tvd_your_key"

The API returns every concept, up to 12 years of history, and point-in-time as_of queries — ask what was knowable on any past date. This page shows only the latest snapshot.

Why does the filing date matter? Read: your backtest saw the future.

Backtest AMGN — and 5,200+ others — without lookahead bias.

Source: U.S. SEC EDGAR (public domain). Values are first-reported (point-in-time); not investment advice. Verify against primary filings before relying on them.